出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年12月
Antibody Therapeutics Market – Global Forecast to 2028
抗体治療市場 : 形式 (モノクローナル、ポリクローナル、抗体断片、二重特異性)、疾患領域 (腫瘍学、自己免疫＆炎症、神経学、血液学、感染症)、原料(ヒト、キメラ)、ルート (IV、SC) – 2028年までの世界予測
Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease area (Oncology, Autoimmune & Inflammatory, Neurology, Hematology, Infectious), Source (Human, Chimeric), Route (IV, SC) – Global Forecast to 2028
| ページ数 | 307 |
| 図表数 | 364 |
| 種別 | 英文調査報告書 |
| 価格 |
Report Overview
The antibody therapeutics market is expected to reach USD 479.0 billion by 2028 from USD 247.3 billion in 2023, at a CAGR of 14.1% during the forecast period. The key factors driving the growth of the antibody therapeutics market include the increasing number of product approvals in the last five years and growing advancements in antibody engineering, among others. Moreover, growth avenues in emerging economies are an opportunity area for this market.
The antibody therapeutics market has been segmented based on format, disease area, route of administration, source, end user and region.
“By source, the human source segment accounted for the largest share of the antibody therapeutics market.”
Based on source, the antibody therapeutics market is categorized into human, humanized, chimeric and other sources. In 2022, humanized sources accounted for the highest growth rate owing to factors such as The rising demand for therapies (including antibody therapy) against cancer, increasing cancer prevalence, high effectiveness of humanized sourced antibodies against cancers and autoimmune & inflammatory diseases are the major factors driving the growth of this segment.
“By route of administration, the intravenous segment accounted for the largest share in the antibody therapeutics market.”
Based on the route of administration, the antibody therapeutics market is segmented into the intravenous, subcutaneous and other routes of administration. In 2022, the intravenous route segment accounted for the largest share of the antibody therapeutics market. Growth in this market segment can be attributed to ease of administration, high effectiveness, presence of large marketed products and major focus of pipeline products on intravenous route.
“North America: the largest share of the antibody therapeutics market.”
North America accounted for the largest share of the antibody therapeutics market. The large share of the North American region can be attributed to major factors such presence of technologically advanced infrastructure in healthcare settings offering antibody therapeutics, and easy accessibility to advanced therapeutics among others. Besides, the region has a well established healthcare system which further supports the growth of this market. Also, the presence of some of the key players in the market is another key factor. Some examples of these players include AbbVie Inc. (US), Johnson & Johnson (US), and Bristol-Myers Squibb (US).
“Europe: The fastest-growing region in the antibody therapeutics market.”
The European antibody therapeutics market is projected to grow at the highest CAGR during the forecast period. This is attributed to one of the major factors including the growing initiatives for advancements of antibody therapeutics, increasing prevalence of chronic diseases and key players such as F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Sanofi (France) operating in the region.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers – 45%, Directors- 30%, and Executives – 25%
• By Region: North America- 25%, Europe- 25%, Asia Pacific- 40%, Latin America- 5%, and Middle East- 3% & Africa- 2%
Prominent Players
• F. Hoffmann-La Roche Ltd. (Switzerland)
• AbbVie Inc. (US)
• Johnson & Johnson (US)
• Merck KGaA (Germany)
• Bristol-Myers Squibb (US)
• AstraZeneca (UK)
• Sanofi (France)
• Regeneron Pharmaceuticals, Inc. (US)
• Novartis AG (Switzerland)
• Amgen, Inc. (US)
• Biogen Inc. (US)
• Takeda Pharmaceutical Company Limited (Japan)
• Pfizer Inc. (US)
• Eli Lilly and Company (US)
• Boehringer Ingelheim International GmbH (Germany)
• GlaxoSmithKline plc (UK)
• UCB, Inc. (Belgium)
• Emergent BioSolutions Inc. (US)
• Y-mAbs Therapeutics, Inc. (US)
• Teva Pharmaceutical Industries Limited (Israel)
• Ultragenyx Pharmaceutical Inc. (US)
• Lundbeck A/S (Denmark)
• Celltrion, Inc. (South Korea)
• MacroGenics, Inc. (US)
• MorphoSys AG (Germany)
Research Coverage:
This report provides a detailed picture of the antibody therapeutics market. It aims at estimating the size and future growth potential of the market across different segments, such as the format, disease area, route of administration, source, end user and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the antibody therapeutics market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges. Additionally, the report is inclusive of extensive product mapping along with their revenues. The report also gives pipeline analysis of antibody therapeutic products which are expected to impact the market significantly during the forecast period.
The report provides insights on the following pointers
• Analysis of key drivers (growth in regulatory approvals for antibody therapeutics products), opportunities (emerging economies), restraint (stringent regulations) and challenges (manufacturing complexities) influencing the growth of the antibody therapeutics market.
• Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the antibody therapeutics market.
• Market Development: Comprehensive information about lucrative markets- the report analyses the antibody therapeutics market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the antibody therapeutics market.
• Analysis of clinical pipeline data and data on products estimated to be launched during the forecast period.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (US), Johnson & Johnson (US), Merck KGaA (Germany), Bristol-Myers Squibb (US), AstraZeneca (UK), Sanofi (France), Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Biogen Inc. (US) among others in the antibody therapeutics market.
Table of Contents
1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS AND EXCLUSIONS 26
1.3 MARKET SCOPE 27
1.3.1 MARKETS COVERED 27
FIGURE 1 ANTIBODY THERAPEUTICS MARKET SEGMENTATION 27
1.3.2 YEARS CONSIDERED 28
1.4 CURRENCY CONSIDERED 28
1.5 STAKEHOLDERS 28
1.6 RECESSION IMPACT 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
FIGURE 2 RESEARCH DESIGN 29
2.1.1 SECONDARY DATA 30
2.1.2 PRIMARY DATA 31
FIGURE 3 ANTIBODY THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES 31
2.2 MARKET SIZE ESTIMATION 32
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 32
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 33
2.2.1 INSIGHTS FROM PRIMARIES 34
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 34
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 35
2.3 GROWTH FORECAST 36
FIGURE 8 ANTIBODY THERAPEUTICS MARKET: CAGR PROJECTIONS 36
FIGURE 9 ANTIBODY THERAPEUTICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 37
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 38
FIGURE 10 DATA TRIANGULATION METHODOLOGY 38
2.5 RESEARCH ASSUMPTIONS 38
2.6 LIMITATIONS 39
2.7 RISK ANALYSIS 39
2.8 RECESSION IMPACT ANALYSIS 40
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 40
3 EXECUTIVE SUMMARY 42
FIGURE 11 ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2023 VS. 2028 (USD BILLION) 42
FIGURE 12 ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2023 VS. 2028 (USD BILLION) 43
FIGURE 13 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD BILLION) 44
FIGURE 14 ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2023 VS. 2028 (USD BILLION) 44
FIGURE 15 ANTIBODY THERAPEUTICS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION) 45
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF ANTIBODY THERAPEUTICS MARKET 46
4 PREMIUM INSIGHTS 47
4.1 ANTIBODY THERAPEUTICS MARKET OVERVIEW 47
FIGURE 17 INCREASING DEMAND FOR ANTIBODY THERAPIES IN TREATMENT OF CANCER TO DRIVE MARKET 47
4.2 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE & COUNTRY (2022) 48
FIGURE 18 HUMAN SOURCES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022 48
4.3 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2023 VS. 2028 (USD MILLION) 48
FIGURE 19 INTRAVENOUS ROUTE OF ADMINISTRATION SEGMENT DOMINATED MARKET IN 2022 48
4.4 ANTIBODY THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49
FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
FIGURE 21 ANTIBODY THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
5.2.1 DRIVERS 51
5.2.1.1 Advancements in antibody engineering 51
5.2.1.2 Rising demand for oncology therapeutics 51
TABLE 2 NUMBER OF APPROVED PRODUCTS BY US FDA/EMA (2015-2023) 52
5.2.1.3 Advantages offered by therapeutic antibodies 52
5.2.1.4 Increasing R&D activities for innovative therapeutics 53
5.2.2 RESTRAINTS 53
5.2.2.1 Stringent regulatory requirements 53
5.2.3 OPPORTUNITIES 54
5.2.3.1 High growth potential of emerging economies 54
5.2.3.2 Growing focus on collaborations for drug discovery & development 54
5.2.4 CHALLENGES 55
5.2.4.1 Complexities associated with manufacturing processes 55
5.3 PORTER’S FIVE FORCES ANALYSIS 56
TABLE 3 ANTIBODY THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 56
5.3.1 THREAT OF NEW ENTRANTS 56
5.3.2 THREAT OF SUBSTITUTES 56
5.3.3 BARGAINING POWER OF SUPPLIERS 56
5.3.4 BARGAINING POWER OF BUYERS 56
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 57
5.4 TECHNOLOGY ANALYSIS 57
5.5 VALUE CHAIN ANALYSIS 58
FIGURE 22 ANTIBODY THERAPEUTICS MARKET: VALUE CHAIN ANALYSIS 58
5.6 ECOSYSTEM ANALYSIS 59
FIGURE 23 ANTIBODY THERAPEUTICS MARKET: ECOSYSTEM MAP 59
5.7 PATENT ANALYSIS 60
FIGURE 24 PATENT APPLICATIONS FOR ANTIBODY THERAPEUTIC PRODUCTS (JANUARY 2012–OCTOBER 2023) 60
TABLE 4 ANTIBODY THERAPEUTICS MARKET: INDICATIVE LIST OF PATENTS 61
5.8 PIPELINE ANALYSIS 62
TABLE 5 ANTIBODY THERAPEUTICS IN CLINICAL PIPELINE 62
5.9 SUPPLY CHAIN ANALYSIS 64
FIGURE 25 ANTIBODY THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS 65
TABLE 6 SUPPLY CHAIN ECOSYSTEM 66
5.10 REGULATORY LANDSCAPE 67
5.10.1 REGULATORY ANALYSIS 67
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION 67
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
5.11 PRICING ANALYSIS 69
5.11.1 AVERAGE SELLING PRICE TREND OF ANTIBODY THERAPEUTICS 69
TABLE 11 AVERAGE SELLING PRICE OF ANTIBODY THERAPEUTICS, BY KEY PLAYER 69
5.11.2 INDICATIVE PRICING ANALYSIS 70
TABLE 12 INDICATIVE PRICING ANALYSIS OF ANTIBODY THERAPEUTIC PRODUCTS, BY ROUTE OF ADMINISTRATION 70
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 71
5.13 KEY CONFERENCES AND EVENTS 72
TABLE 13 ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023–2024) 72
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 73
5.14.1 KEY STAKEHOLDERS ON BUYING PROCESS 73
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR ANTIBODY THERAPEUTICS 73
5.14.2 BUYING CRITERIA FOR ANTIBODY THERAPEUTICS MARKET 73
FIGURE 27 KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES 73
6 ANTIBODY THERAPEUTICS MARKET, BY FORMAT 74
6.1 INTRODUCTION 75
TABLE 14 ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 75
6.2 MONOCLONAL ANTIBODIES 75
6.2.1 TARGET SPECIFICITY AND GROWING CLINICAL PIPELINE OF MABS TO DRIVE MARKET 75
TABLE 15 APPROVED MONOCLONAL ANTIBODIES 76
TABLE 16 ANTIBODY THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 77
TABLE 17 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 18 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 19 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 20 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 79
6.3 POLYCLONAL ANTIBODIES 79
6.3.1 BROADER SPECTRUM OF TARGETS OFFERED BY POLYCLONAL ANTIBODIES TO SUPPORT MARKET GROWTH 79
TABLE 21 APPROVED POLYCLONAL ANTIBODIES 80
TABLE 22 ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 80
TABLE 23 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 24 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 25 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 26 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR POLYCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 82
6.4 ANTIBODY FRAGMENTS 82
6.4.1 WIDE APPLICATIONS OF ANTIBODY FRAGMENTS IN ONCOLOGY TO FUEL GROWTH 82
TABLE 27 APPROVED ANTIBODY FRAGMENTS 83
TABLE 28 ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY REGION, 2021–2028 (USD MILLION) 83
TABLE 29 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 30 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 31 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 32 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR ANTIBODY FRAGMENTS, BY COUNTRY, 2021–2028 (USD MILLION) 84
6.5 BISPECIFIC ANTIBODIES 85
6.5.1 MINIMAL SIDE EFFECTS OF BISPECIFIC ANTIBODIES DUE TO TARGETED APPROACH TO FUEL ADOPTION 85
TABLE 33 APPROVED BISPECIFIC ANTIBODIES 85
TABLE 34 ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY REGION, 2021–2028 (USD MILLION) 86
TABLE 35 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 36 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 37 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 38 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR BISPECIFIC ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION) 87
6.6 OTHER NOVEL ANTIBODY THERAPIES 88
TABLE 39 APPROVED NOVEL ANTIBODY THERAPIES 88
TABLE 40 ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY REGION, 2021–2028 (USD MILLION) 88
TABLE 41 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 42 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 43 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 44 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER NOVEL ANTIBODY THERAPIES, BY COUNTRY, 2021–2028 (USD MILLION) 90
7 ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA 91
7.1 INTRODUCTION 92
TABLE 45 ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 92
7.2 AUTOIMMUNE & INFLAMMATORY DISEASES 92
7.2.1 LARGE NUMBER OF MARKETED ANTIBODY THERAPEUTICS AND STRONG PIPELINE TO DRIVE MARKET 92
TABLE 46 ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2021–2028 (USD MILLION) 93
TABLE 47 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 48 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 49 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 50 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 95
7.3 ONCOLOGY 95
7.3.1 INITIATIVES BY MARKET PLAYERS TO DEVELOP ANTIBODY THERAPIES FOR CANCER INDICATIONS TO SUPPORT GROWTH 95
TABLE 51 ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 96
TABLE 52 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 53 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 54 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 55 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 97
7.4 HEMATOLOGY 98
7.4.1 GROWING PRODUCT ADOPTION TO SUPPORT MARKET GROWTH 98
TABLE 56 ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2021–2028 (USD MILLION) 98
TABLE 57 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 58 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 59 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 60 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 100
7.5 INFECTIOUS DISEASES 100
7.5.1 GROWING RESEARCH FOCUS ON INFECTIOUS DISEASES TO FUEL MARKET GROWTH 100
TABLE 61 ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 101
TABLE 62 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 63 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 64 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 65 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 102
7.6 OSTEOLOGY 103
7.6.1 GROWING FOCUS ON OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN TO SUPPORT GROWTH 103
TABLE 66 ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY REGION, 2021–2028 (USD MILLION) 103
TABLE 67 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 68 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 69 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 104
TABLE 70 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OSTEOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 105
7.7 IMMUNOLOGY 105
7.7.1 GROWING USE OF HUMORAL IMMUNODEFICIENCY ANTIBODY THERAPEUTICS TO PROPEL MARKET GROWTH 105
TABLE 71 ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY REGION, 2021–2028 (USD MILLION) 106
TABLE 72 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 73 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 74 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 75 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 107
7.8 NEUROLOGY 108
7.8.1 PRESENCE OF SEVERAL MONOCLONAL ANTIBODIES FOR NEUROLOGICAL CONDITIONS TO FUEL MARKET GROWTH 108
TABLE 76 ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 77 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 78 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 79 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 80 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 110
7.9 OTHER DISEASE AREAS 110
TABLE 81 ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021–2028 (USD MILLION) 110
TABLE 82 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 83 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 84 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 85 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 112
8 ANTIBODY THERAPEUTICS MARKET, BY SOURCE 113
8.1 INTRODUCTION 114
TABLE 86 ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 114
8.2 HUMAN 114
8.2.1 REDUCED IMMUNOGENICITY OF HUMAN-SOURCED ANTIBODIES TO DRIVE GROWTH 114
TABLE 87 ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY REGION, 2021–2028 (USD MILLION) 115
TABLE 88 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 89 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 90 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 91 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 117
8.3 HUMANIZED 117
8.3.1 EFFECTIVENESS OF HUMANIZED ANTIBODY THERAPEUTICS AGAINST CANCER AND AUTOIMMUNE & INFLAMMATORY DISORDERS TO DRIVE DEMAND 117
TABLE 92 ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 93 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 94 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 95 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 96 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 119
8.4 CHIMERIC 120
8.4.1 INTRODUCTION OF HYBRID DESIGNS RESULTING IN IMPROVED EFFICACY TO SUPPORT MARKET GROWTH 120
TABLE 97 ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 98 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 99 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 100 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 101 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 122
8.5 OTHER SOURCES 122
TABLE 102 ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2021–2028 (USD MILLION) 122
TABLE 103 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 104 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 105 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 106 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2021–2028 (USD MILLION) 124
9 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION 125
9.1 INTRODUCTION 126
TABLE 107 ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 126
9.2 INTRAVENOUS 126
9.2.1 EFFECTIVENESS OF INTRAVENOUS PRODUCTS TO SUPPORT MARKET GROWTH 126
TABLE 108 ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION) 127
TABLE 109 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 110 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 111 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 112 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 128
9.3 SUBCUTANEOUS 129
9.3.1 ADVANTAGES SUCH AS FASTER ONSET OF THERAPEUTIC EFFECT TO BOOST DEMAND 129
TABLE 113 ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 114 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 115 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 116 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 117 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 131
9.4 OTHER ROUTES OF ADMINISTRATION 132
TABLE 118 ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2021–2028 (USD MILLION) 132
TABLE 119 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 120 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 121 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 122 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2021–2028 (USD MILLION) 133
10 ANTIBODY THERAPEUTICS MARKET, BY END USER 134
10.1 INTRODUCTION 135
TABLE 123 ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 135
10.2 HOSPITALS 135
10.2.1 AVAILABILITY OF ADVANCED FACILITIES AND SUPPORT TO DRIVE MARKET 135
TABLE 124 ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION) 136
TABLE 125 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 126 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 127 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 128 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION) 137
10.3 LONG-TERM CARE FACILITIES 138
10.3.1 ADVANTAGES SUCH AS SPECIALIZED CARE AND MONITORING TO SUPPORT MARKET GROWTH 138
TABLE 129 ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2021–2028 (USD MILLION) 138
TABLE 130 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 131 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 132 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 133 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2021–2028 (USD MILLION) 139
10.4 OTHER END USERS 140
TABLE 134 ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 140
TABLE 135 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 140
TABLE 136 EUROPE: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 137 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 138 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 141
11 ANTIBODY THERAPEUTICS MARKET, BY REGION 142
11.1 INTRODUCTION 143
TABLE 139 ANTIBODY THERAPEUTICS MARKET, BY REGION, 2021–2028 (USD MILLION) 143
11.2 NORTH AMERICA 143
FIGURE 28 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET SNAPSHOT 144
TABLE 140 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 141 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 145
TABLE 142 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 146
TABLE 143 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 146
TABLE 144 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 147
TABLE 145 NORTH AMERICA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 147
11.2.1 US 147
11.2.1.1 Growing FDA approvals for novel antibody therapeutics to drive market 147
TABLE 146 US FDA ANTIBODY THERAPEUTIC PRODUCT APPROVALS 148
TABLE 147 US: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 149
TABLE 148 US: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 149
TABLE 149 US: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 150
TABLE 150 US: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 150
TABLE 151 US: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 150
11.2.2 CANADA 151
11.2.2.1 Growing cancer burden and investments in antibody research to support market growth 151
TABLE 152 CANADA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 151
TABLE 153 CANADA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 152
TABLE 154 CANADA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 152
TABLE 155 CANADA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 153
TABLE 156 CANADA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 153
11.2.3 NORTH AMERICA: RECESSION IMPACT 153
11.3 EUROPE 154
FIGURE 29 EUROPE: ANTIBODY THERAPEUTICS MARKET SNAPSHOT 155
TABLE 157 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 158 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 156
TABLE 159 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 157
TABLE 160 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 157
TABLE 161 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 158
TABLE 162 EUROPE: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 158
11.3.1 GERMANY 158
11.3.1.1 Rising incidence of cancer to drive market 158
TABLE 163 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 159
TABLE 164 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 159
TABLE 165 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 160
TABLE 166 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 160
TABLE 167 GERMANY: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 160
11.3.2 UK 161
11.3.2.1 Growing research initiatives to support market growth 161
TABLE 168 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 161
TABLE 169 UK: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 161
TABLE 170 UK: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 162
TABLE 171 UK: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 162
TABLE 172 UK: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 163
TABLE 173 UK: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 163
11.3.3 FRANCE 163
11.3.3.1 Favorable reimbursement policies to drive growth 163
TABLE 174 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 164
TABLE 175 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 164
TABLE 176 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 165
TABLE 177 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 165
TABLE 178 FRANCE: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 165
11.3.4 ITALY 166
11.3.4.1 Growing regulatory approvals for antibody therapeutics to support growth 166
TABLE 179 ITALY: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 166
TABLE 180 ITALY: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 167
TABLE 181 ITALY: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 167
TABLE 182 ITALY: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 168
TABLE 183 ITALY: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 168
11.3.5 SPAIN 168
11.3.5.1 Growing prevalence of cancer to drive market 168
TABLE 184 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 169
TABLE 185 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 169
TABLE 186 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 170
TABLE 187 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 170
TABLE 188 SPAIN: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 170
11.3.6 REST OF EUROPE 171
TABLE 189 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 171
TABLE 190 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 172
TABLE 191 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 172
TABLE 192 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 173
TABLE 193 REST OF EUROPE: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 173
11.3.7 EUROPE: RECESSION IMPACT 173
11.4 ASIA PACIFIC 174
TABLE 194 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 174
TABLE 195 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 175
TABLE 196 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 175
TABLE 197 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 176
TABLE 198 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 176
TABLE 199 ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 176
11.4.1 CHINA 177
11.4.1.1 Growing demand for therapeutic products to support growth 177
TABLE 200 CHINA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 177
TABLE 201 CHINA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 178
TABLE 202 CHINA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 178
TABLE 203 CHINA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 179
TABLE 204 CHINA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 179
11.4.2 JAPAN 179
11.4.2.1 Growing access to quality healthcare to boost market 179
TABLE 205 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 180
TABLE 206 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 180
TABLE 207 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 181
TABLE 208 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 181
TABLE 209 JAPAN: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 181
11.4.3 INDIA 182
11.4.3.1 Increasing burden of chronic diseases and growing R&D initiatives to drive market 182
TABLE 210 INDIA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 182
TABLE 211 INDIA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 183
TABLE 212 INDIA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 183
TABLE 213 INDIA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 184
TABLE 214 INDIA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 184
11.4.4 SOUTH KOREA 184
11.4.4.1 Favorable government initiatives to propel market 184
TABLE 215 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 185
TABLE 216 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 185
TABLE 217 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 186
TABLE 218 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 186
TABLE 219 SOUTH KOREA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 186
11.4.5 REST OF ASIA PACIFIC 187
TABLE 220 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 187
TABLE 221 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 188
TABLE 222 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 188
TABLE 223 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 189
TABLE 224 REST OF ASIA PACIFIC: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 189
11.4.6 ASIA PACIFIC: RECESSION IMPACT 189
11.5 LATIN AMERICA 190
TABLE 225 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 190
TABLE 226 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 190
TABLE 227 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 191
TABLE 228 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 191
TABLE 229 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 192
TABLE 230 LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 192
11.5.1 BRAZIL 192
11.5.1.1 Growing demand for therapeutics against chronic diseases to drive market 192
TABLE 231 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 193
TABLE 232 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 193
TABLE 233 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 194
TABLE 234 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 194
TABLE 235 BRAZIL: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 194
11.5.2 REST OF LATIN AMERICA 195
TABLE 236 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 195
TABLE 237 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 196
TABLE 238 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 196
TABLE 239 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 197
TABLE 240 REST OF LATIN AMERICA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 197
11.5.3 LATIN AMERICA: RECESSION IMPACT 197
11.6 MIDDLE EAST 198
11.6.1 DEVELOPING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET 198
TABLE 241 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 198
TABLE 242 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 199
TABLE 243 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 199
TABLE 244 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 200
TABLE 245 MIDDLE EAST: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 200
11.6.2 MIDDLE EAST: RECESSION IMPACT 200
11.7 AFRICA 201
11.7.1 INCREASING PUBLIC AND PRIVATE INVESTMENTS IN HEALTHCARE TO SUPPORT MARKET GROWTH 201
TABLE 246 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY FORMAT, 2021–2028 (USD MILLION) 201
TABLE 247 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY DISEASE AREA, 2021–2028 (USD MILLION) 202
TABLE 248 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2021–2028 (USD MILLION) 202
TABLE 249 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2021–2028 (USD MILLION) 203
TABLE 250 AFRICA: ANTIBODY THERAPEUTICS MARKET, BY END USER, 2021–2028 (USD MILLION) 203
11.7.2 AFRICA: RECESSION IMPACT 203
12 COMPETITIVE LANDSCAPE 204
12.1 INTRODUCTION 204
12.2 KEY STRATEGIES/RIGHT TO WIN 204
FIGURE 30 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIBODY THERAPEUTICS MARKET 205
12.3 MARKET SHARE ANALYSIS 205
FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022 206
TABLE 251 DEGREE OF COMPETITION: ANTIBODY THERAPEUTICS MARKET 206
12.4 MARKET REVENUE ANALYSIS 207
FIGURE 32 REVENUE ANALYSIS FOR KEY COMPANIES, 2020–2022 207
12.5 COMPANY EVALUATION MATRIX 208
12.5.1 STARS 208
12.5.2 EMERGING LEADERS 208
12.5.3 PERVASIVE PLAYERS 208
12.5.4 PARTICIPANTS 208
FIGURE 33 COMPANY EVALUATION MATRIX, 2022 209
12.5.5 COMPANY FOOTPRINT 210
12.5.5.1 Product footprint 210
TABLE 252 PRODUCT FOOTPRINT OF KEY PLAYERS 210
12.5.5.2 Regional footprint 211
TABLE 253 REGIONAL FOOTPRINT OF KEY PLAYERS 211
12.6 START-UP/SME EVALUATION MATRIX 212
12.6.1 PROGRESSIVE COMPANIES 212
12.6.2 RESPONSIVE COMPANIES 212
12.6.3 DYNAMIC COMPANIES 212
12.6.4 STARTING BLOCKS 212
FIGURE 34 START-UP/SME EVALUATION MATRIX, 2022 213
12.6.5 COMPETITIVE BENCHMARKING 214
TABLE 254 DETAILED LIST OF KEY START-UPS/SMES 214
TABLE 255 COMPETITIVE BENCHMARKING OF START-UPS/SMES 214
12.7 COMPETITIVE SCENARIOS AND TRENDS 215
12.7.1 PRODUCT APPROVALS 215
TABLE 256 PRODUCT APPROVALS, JANUARY 2020–SEPTEMBER 2023 215
12.7.2 DEALS 216
TABLE 257 DEALS, JANUARY 2020–SEPTEMBER 2023 216
12.7.3 OTHER DEVELOPMENTS 216
TABLE 258 OTHER DEVELOPMENTS, JANUARY 2020–SEPTEMBER 2023 216
13 COMPANY PROFILES 217
(Business overview, Products/Services/Solutions offered, Recent developments & MnM View)*
13.1 KEY PLAYERS 217
13.1.1 F. HOFFMANN-LA ROCHE LTD. 217
TABLE 259 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 217
FIGURE 35 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 218
TABLE 260 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES 222
TABLE 261 F. HOFFMANN-LA ROCHE LTD.: PRODUCT APPROVALS 222
TABLE 262 F. HOFFMANN-LA ROCHE LTD.: DEALS 224
13.1.2 ABBVIE INC. 225
TABLE 263 ABBVIE INC.: COMPANY OVERVIEW 225
FIGURE 36 ABBVIE INC.: COMPANY SNAPSHOT (2022) 226
TABLE 264 ABBVIE INC.: PRODUCT APPROVALS 227
TABLE 265 ABBVIE INC.: DEALS 227
13.1.3 JOHNSON & JOHNSON 229
TABLE 266 JOHNSON & JOHNSON: COMPANY OVERVIEW 229
FIGURE 37 JOHNSON & JOHNSON: COMPANY SNAPSHOT 230
TABLE 267 JOHNSON & JOHNSON: PRODUCT APPROVALS 232
13.1.4 MERCK KGAA 234
TABLE 268 MERCK KGAA: COMPANY OVERVIEW 234
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2022) 235
TABLE 269 MERCK KGAA: PRODUCT APPROVALS 236
TABLE 270 MERCK KGAA: OTHER DEVELOPMENTS 236
13.1.5 BRISTOL-MYERS SQUIBB 238
TABLE 271 BRISTOL-MYERS SQUIBB: COMPANY OVERVIEW 238
FIGURE 39 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2022) 239
TABLE 272 BRISTOL-MYERS SQUIBB: PRODUCT APPROVALS 240
TABLE 273 BRISTOL-MYERS SQUIBB: DEALS 242
TABLE 274 BRISTOL-MYERS SQUIBB: OTHER DEVELOPMENTS 243
13.1.6 ASTRAZENECA 244
TABLE 275 ASTRAZENECA: COMPANY OVERVIEW 244
FIGURE 40 ASTRAZENECA: COMPANY SNAPSHOT (2022) 244
TABLE 276 ASTRAZENECA: DEALS 246
TABLE 277 ASTRAZENECA: PRODUCT APPROVALS 246
13.1.7 SANOFI 249
TABLE 278 SANOFI: COMPANY OVERVIEW 249
FIGURE 41 SANOFI: COMPANY SNAPSHOT (2022) 250
TABLE 279 SANOFI: PRODUCT APPROVALS 252
TABLE 280 SANOFI: DEALS 253
13.1.8 REGENERON PHARMACEUTICALS INC. 254
TABLE 281 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW 254
FIGURE 42 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT 254
TABLE 282 REGENERON PHARMACEUTICALS INC.: DEALS 255
TABLE 283 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS 256
13.1.9 NOVARTIS AG 258
TABLE 284 NOVARTIS AG: COMPANY OVERVIEW 258
FIGURE 43 NOVARTIS AG: COMPANY SNAPSHOT (2022) 259
TABLE 285 NOVARTIS AG: DEALS 261
TABLE 286 NOVARTIS AG: PRODUCT APPROVALS 261
TABLE 287 NOVARTIS AG: OTHER DEVELOPMENTS 262
13.1.10 AMGEN INC. 263
TABLE 288 AMGEN INC.: COMPANY OVERVIEW 263
FIGURE 44 AMGEN INC.: COMPANY SNAPSHOT (2022) 264
TABLE 289 AMGEN INC.: DEALS 266
TABLE 290 AMGEN INC.: PRODUCT APPROVALS 266
TABLE 291 AMGEN INC.: OTHER DEVELOPMENTS 266
13.1.11 BIOGEN 267
TABLE 292 BIOGEN: COMPANY OVERVIEW 267
FIGURE 45 BIOGEN INC.: COMPANY SNAPSHOT (2022) 268
TABLE 293 BIOGEN: PRODUCT APPROVALS 269
TABLE 294 BIOGEN: DEALS 269
13.1.12 TAKEDA PHARMACEUTICAL COMPANY LIMITED 270
TABLE 295 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW 270
FIGURE 46 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022) 271
TABLE 296 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS 272
13.1.13 PFIZER INC. 273
TABLE 297 PFIZER INC.: COMPANY OVERVIEW 273
FIGURE 47 PFIZER INC.: COMPANY SNAPSHOT 274
TABLE 298 PFIZER INC.: PRODUCT APPROVALS 275
13.1.14 ELI LILLY AND COMPANY 276
TABLE 299 ELI LILLY AND COMPANY: COMPANY OVERVIEW 276
FIGURE 48 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 277
TABLE 300 ELI LILLY AND COMPANY: PRODUCT APPROVALS 278
TABLE 301 ELI LILLY AND COMPANY: DEALS 279
TABLE 302 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS 279
13.1.15 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 280
TABLE 303 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 280
FIGURE 49 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022) 281
TABLE 304 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS 282
TABLE 305 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT APPROVALS 283
TABLE 306 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS 283
13.1.16 GLAXOSMITHKLINE PLC 284
TABLE 307 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW 284
FIGURE 50 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2022) 285
TABLE 308 GLAXOSMITHKLINE PLC: DEALS 286
TABLE 309 GLAXOSMITHKLINE PLC: PRODUCT APPROVALS 287
TABLE 310 GLAXOSMITHKLINE PLC: OTHER DEVELOPMENTS 287
13.1.17 UCB S.A. 288
TABLE 311 UCB S.A.: COMPANY OVERVIEW 288
FIGURE 51 UCB S.A.: COMPANY SNAPSHOT (2022) 288
TABLE 312 UCB S.A.: DEALS 289
TABLE 313 UCB S.A.: PRODUCT APPROVALS 290
*Details on Business overview, Products/Services/Solutions offered, Recent developments & MnM View might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS 291
13.2.1 EMERGENT BIOSOLUTIONS INC. 291
13.2.2 Y-MABS THERAPEUTICS, INC. 292
13.2.3 TEVA PHARMACEUTICAL INDUSTRIES LTD. 293
13.2.4 ULTRAGENYX PHARMACEUTICAL INC. 294
13.2.5 H. LUNDBECK A/S 294
13.2.6 CELLTRION INC. 295
13.2.7 MACROGENICS, INC. 295
13.2.8 MORPHOSYS AG 296
14 APPENDIX 297
14.1 DISCUSSION GUIDE 297
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 302
14.3 CUSTOMIZATION OPTIONS 304
14.4 RELATED REPORTS 305
14.5 AUTHOR DETAILS 306